MA55821B1 - Antagonistes 5-ht2a destinés à être utilisés dans le traitement de la dépression - Google Patents

Antagonistes 5-ht2a destinés à être utilisés dans le traitement de la dépression

Info

Publication number
MA55821B1
MA55821B1 MA55821A MA55821A MA55821B1 MA 55821 B1 MA55821 B1 MA 55821B1 MA 55821 A MA55821 A MA 55821A MA 55821 A MA55821 A MA 55821A MA 55821 B1 MA55821 B1 MA 55821B1
Authority
MA
Morocco
Prior art keywords
treatment
ht2a
depression
relates
ht2a antagonists
Prior art date
Application number
MA55821A
Other languages
English (en)
Other versions
MA55821A (fr
Inventor
Jesper Langgaard Kristensen
Anders Asbjørn Jensen
Emil Märcher-Rørsted
Sebastian Leth-Petersen
Original Assignee
Lophora ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lophora ApS filed Critical Lophora ApS
Publication of MA55821A publication Critical patent/MA55821A/fr
Publication of MA55821B1 publication Critical patent/MA55821B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)

Abstract

La présente invention concerne des antagonistes des récepteurs 5-ht2a de la sérotonine et leurs utilisations médicales. Selon un aspect, l'invention concerne des agonistes 5-ht2a de formule (i). Selon un autre aspect, l'invention concerne des antagonistes 5-ht2a destinés à être utilisés dans le traitement d'un trouble dépressif, en particulier un antagoniste 5-ht2a destiné à être utilisé dans le traitement des dépressions pharmacorésistantes.
MA55821A 2019-11-07 2020-11-06 Antagonistes 5-ht2a destinés à être utilisés dans le traitement de la dépression MA55821B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19207578 2019-11-07
PCT/EP2020/081357 WO2021089824A1 (fr) 2019-11-07 2020-11-06 Antagonistes 5-ht2a destinés à être utilisés dans le traitement de la dépression

Publications (2)

Publication Number Publication Date
MA55821A MA55821A (fr) 2022-05-04
MA55821B1 true MA55821B1 (fr) 2023-08-31

Family

ID=68502828

Family Applications (1)

Application Number Title Priority Date Filing Date
MA55821A MA55821B1 (fr) 2019-11-07 2020-11-06 Antagonistes 5-ht2a destinés à être utilisés dans le traitement de la dépression

Country Status (20)

Country Link
US (3) US11246860B2 (fr)
EP (1) EP3962601B1 (fr)
JP (1) JP7566021B2 (fr)
CN (1) CN114761083B (fr)
BR (1) BR112022008037A2 (fr)
CA (1) CA3156513A1 (fr)
DK (1) DK3962601T3 (fr)
ES (1) ES2953926T3 (fr)
FI (1) FI3962601T3 (fr)
HR (1) HRP20230856T1 (fr)
HU (1) HUE062369T2 (fr)
IL (1) IL292585B2 (fr)
LT (1) LT3962601T (fr)
MA (1) MA55821B1 (fr)
MD (1) MD3962601T2 (fr)
PL (1) PL3962601T3 (fr)
PT (1) PT3962601T (fr)
SI (1) SI3962601T1 (fr)
WO (1) WO2021089824A1 (fr)
ZA (1) ZA202204809B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11246860B2 (en) * 2019-11-07 2022-02-15 Lophora ApS 5-HT2A agonists for use in treatment of depression
JP7766623B2 (ja) 2020-05-19 2025-11-10 サイビン アイアールエル リミテッド 重水素化トリプタミン誘導体および使用方法
KR20230053611A (ko) 2020-08-18 2023-04-21 사이빈 아이알엘 리미티드 펜에틸아민 유도체, 조성물, 및 사용 방법
EP4329759A4 (fr) 2021-04-30 2025-07-16 Mind Medicine Inc Formes cristallines de sels de lsd
CN117222623A (zh) * 2021-05-06 2023-12-12 罗弗拉有限公司 (s)-3-(2,5-二甲氧基-4-(三氟甲基)苯基)哌啶和(s)-3-(2-甲氧基-5-(甲硫基)-4-(三氟甲基)苯基)哌啶的酸加成盐，其特定多晶型物及其制备方法
AU2022317782A1 (en) * 2021-07-26 2024-01-25 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compounds and methods for treating 5-ht2 responsive conditions
EP4387624A4 (fr) 2021-08-19 2025-07-30 Mind Medicine Inc Formulations à libération immédiate de diéthylamide de l'acide d-lysergique pour des applications thérapeutiques
WO2024181024A1 (fr) * 2023-03-02 2024-09-06 本田技研工業株式会社 Composition
WO2025008804A1 (fr) * 2023-07-06 2025-01-09 M – Path Biopharma Ltd. Polythérapie pour apporter des améliorations aux effets secondaires d'un traitement par inhibiteurs des récepteurs des œstrogènes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1330448A2 (fr) 2000-06-20 2003-07-30 Atherogenics, Inc. 1,3-bis-(phenyl substitue)-2-propene-1-ones et leur utilisation dans le traitement des troubles vehicules par vcam-1
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
US11246860B2 (en) * 2019-11-07 2022-02-15 Lophora ApS 5-HT2A agonists for use in treatment of depression

Also Published As

Publication number Publication date
LT3962601T (lt) 2023-09-11
CA3156513A1 (fr) 2021-05-14
US20210330658A1 (en) 2021-10-28
US11246860B2 (en) 2022-02-15
JP2023501275A (ja) 2023-01-18
HRP20230856T1 (hr) 2023-11-10
DK3962601T3 (da) 2023-09-04
HUE062369T2 (hu) 2023-10-28
US20210137908A1 (en) 2021-05-13
ES2953926T3 (es) 2023-11-17
EP3962601B1 (fr) 2023-05-31
US11633390B2 (en) 2023-04-25
AU2020379225A1 (en) 2022-05-26
PL3962601T3 (pl) 2023-10-09
BR112022008037A2 (pt) 2022-07-12
ZA202204809B (en) 2022-11-30
CN114761083A (zh) 2022-07-15
IL292585B2 (en) 2023-08-01
WO2021089824A1 (fr) 2021-05-14
FI3962601T3 (fi) 2023-08-09
MA55821A (fr) 2022-05-04
IL292585B1 (en) 2023-04-01
SI3962601T1 (sl) 2023-10-30
MD3962601T2 (ro) 2023-10-31
CN114761083B (zh) 2024-02-13
PT3962601T (pt) 2023-08-28
IL292585A (en) 2022-06-01
JP7566021B2 (ja) 2024-10-11
US20220062257A1 (en) 2022-03-03
EP3962601A1 (fr) 2022-03-09
US11642336B2 (en) 2023-05-09

Similar Documents

Publication Publication Date Title
MA55821B1 (fr) Antagonistes 5-ht2a destinés à être utilisés dans le traitement de la dépression
MA57972B1 (fr) Inhibiteurs de parp1
MA45782B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA39094A1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
CY1125348T1 (el) Νεοι ανταγωνιστες υποδοχεων β2 βραδυκινινης
MA40893B1 (fr) Dérivés de phényltriazole à substitution hydroxyalkyle et utilisations associées
MA45020A (fr) Dérivés sulfonamides aromatiques
MA42109B1 (fr) Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase
MA41135B1 (fr) Benzamides substitués 1,3-thiazol-2-yl
MA41562A1 (fr) Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires
MA49127B1 (fr) Dérivés d'indole n-substitués
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
MA43409B1 (fr) Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton
JOP20220160A1 (ar) مركبات فعّالة نحو مستقبلات نووية
MA41633B1 (fr) Composés amide en tant qu'agonistes du récepteur 5-ht4
MA39164A1 (fr) Forme de sel cristalline de (s)-(2-(6-chloro-7-méthyl-1 h-benzo[d]imidazol- 2-yl)-2-méthylpyrrolidin-1-yl)(5-méthoxy-2-(2h-1,2,3-triazol-2-yl)phényl)méthanone comme antagoniste des récepteurs à l'oréxine
MA38358A1 (fr) Formulations de composés organiques
EA202191620A1 (ru) Твердые формы, содержащие (s)-4-(4-(4-(((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-4-ил)окси)метил)бензил)пиперазин-1-ил)-3-фторбензонитрил и его соли, и содержащие их композиции и способы их применения
MA38679A1 (fr) Modulateurs du récepteur de cxcr7
MA39253A1 (fr) Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr
GEP20257744B (en) Antimalarial agents
PH12021550549A1 (en) Dp antagonist
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines
MA45002B1 (fr) Triple combinaison d'antagonistes purs du récepteurs 5-ht6, d'inhibiteurs de l'acétylcholinestérase et d'antagonistes du récepteur nmda
MA41311B1 (fr) Peptides antagonistes du cgrp